You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service

Article info

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service

Authors

  • Osama Abu-Shawer Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Prabhsimranjot Singh Harvard Medical School, Boston, Massachusetts, USA Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Eric Yenulevich Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Amanda Brito Harvard Medical School, Boston, Massachusetts, USA Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Jian Ni Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Raja-Elie E Abdulnour Harvard Medical School, Boston, Massachusetts, USA Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Shilpa Grover Harvard Medical School, Boston, Massachusetts, USA Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Michael Manos Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Peter Bowling Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Nicole R LeBoeuf Harvard Medical School, Boston, Massachusetts, USA Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Patrick Ott Harvard Medical School, Boston, Massachusetts, USA Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • F Stephen Hodi Harvard Medical School, Boston, Massachusetts, USA Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Joseph Jacobson Harvard Medical School, Boston, Massachusetts, USA Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Osama Rahma Harvard Medical School, Boston, Massachusetts, USA Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Osama Rahma; osamae_rahma{at}dfci.harvard.edu
View Full Text

Citation

Abu-Shawer O, Singh P, Yenulevich E, et al
Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service
Journal for ImmunoTherapy of Cancer 2020;8:e000992. doi: 10.1136/jitc-2020-000992

Publication history

  • Accepted July 5, 2020
  • First published August 18, 2020.
Online issue publication 
August 18, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.